A phase I/IIA study of AGS-PSCA for castration-resistant prostate cancer

Annals of Oncology, 05/04/2012

A 40–mg/kg loading dose followed by 20–mg/kg infusions every 3weeks is the recommended phase II dose of AGS–prostate stem cell antigen (PSCA). PSCA is a promising drug target and studies in prostate and other relevant solid tumors are planned.

Print Article Summary